Patient 1
Consider adding Optune Gio for older patients like this one1
Patient 1
76 years old
Biopsy only
MGMT-methylated
- Married, 4 grandchildren
- Retired painter
- Supported by his wife and daughter
Real patient profile provided by Kellie Kopp, RN, BSN, OCN.
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
- Optune Gio + adjuvant chemotherapy initiated 6 weeks after chemoradiation
- Temozolomide completed after 7 monthly cycles at 150 mg/m2 (dosing due to fatigue and thrombocytopenia)
Side effect management
Chemoradiation therapy
Effects: Minimal side effects reported; mild fatigue, and constipation. Patient reported continued fatigue and thrombocytopenia during monthly temozolomide
Management: Stool softener; temozolomide dose reduced from 200 mg/m2 to 150 mg/m2
Optune Gio
Effects: Reported that his face “was red, like a sunburn and hot to touch” after first initiating Optune Gio and wearing for 50 hours straight
Management: A short treatment break and reapplication of arrays. No further skin issues were reported. Readdressed usage and continued compliance with each visit
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient’s MRI
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient’s usage report1
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
MGMT, O-6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; ED, emergency department; WHO, World Health Organization; MRI, magnetic resonance imaging.
Reference: 1. Novocure Data on File OPT-05289.